Clin Lymphoma Myeloma Leuk. 2017 Dec 6. pii: S2152-2650(17)31539-2. doi: 10.1016/j.clml.2017.11.010. [Epub ahead of print]
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
Mato A1, Nabhan C2, Kay NE3, Lamanna N4, Kipps TJ5, Grinblatt DL6, Flowers CR7, Farber CM8, Davids MS9, Kiselev P10, Swern AS10, Bhushan S10, Sullivan K11, Flick ED12, Sharman JP13.
PATIENTS AND METHODS:
In the present analysis of the Connect CLL Registry (ClinicalTrials.gov identifier, NCT01081015), a prospective observational cohort study of patients treated across 199 centers, the patterns of prognostic testing and outcomes of patients with unfavorable-risk genetics were analyzed. From 2010 to 2014, 1494 treated patients were enrolled in the registry by line of therapy (LOT), and stratified by the results of cytogenetic/fluorescence in situ hybridization (FISH) testing into 3 risk levels: unfavorable (presence of del[17p] or del[11q]), favorable (absence of del[17p] and del[11q]), and unknown.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Community setting; Cytogenetic testing; Kinase inhibitor; Prognosis; Unfavorable risk